Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC

Adding the checkpoint inhibitor atezolizumab to chemotherapy prolonged overall survival significantly better than chemotherapy alone in patients with ES-SCLC.

from Latest articles from Cancer Therapy Advisor News https://ift.tt/2xNDzox